文献速递消化道肿瘤与早癌消化内镜

新型微生物组特征用于结肠镜息肉切除术后腺瘤复发的无创诊断

Novel microbiome signatures for non-invasive diagnosis of adenoma recurrence after colonoscopic polypectomy.
PubMed 文献 · Aliment Pharmacol Ther · 2022-02-27

本研究基于2009至2019年息肉监测研究,评估粪便微生物组基因标志物检测息肉切除术后腺瘤复发的价值。共分析161份基线和104份随访粪便样本,随访时m3、Fn和Ch变化组合检测复发的AUROC为0.95(95%CI: 0.84-0.99),灵敏度90.0%、特异度87.0%;粪便免疫化学试验灵敏度仅8.3%。作者认为该组合可能成为无创检测腺瘤复发的工具。

要点

  • 随访时m3、Fn和Ch变化组合检测腺瘤复发AUROC为0.95,灵敏度90.0%、特异度87.0%。
  • 随访时m3、Fn和Ch组合检测腺瘤复发AUROC为0.74,灵敏度81.3%、特异度55.4%。
  • 粪便免疫化学试验检测复发腺瘤灵敏度仅8.3%。

核心结论

  • 粪便微生物组基因标志物组合可能成为检测腺瘤复发的无创工具。

研究设计与样本

  • 研究纳入2009至2019年息肉监测研究的受试者,在指数结肠镜肠道准备前(基线)和监测结肠镜前(随访)采集粪便样本。
  • 通过定量聚合酶链反应(qPCR)定量Fn、m3、Ch和Bacteroides clarus,并与腺瘤复发进行关联分析。
  • 复发定义为息肉切除术后>6个月检出新的腺瘤。
  • 共分析161份基线样本和104份随访样本。

主要发现

  • 在腺瘤复发患者中,随访样本较基线样本Fn和m3升高(均P < 0.05),Ch无变化。
  • 在无复发患者中,随访样本较基线样本Fn和m3无变化,Ch降低(P < 0.05)。
  • 包含随访时m3、Fn和Ch较基线变化的logistic回归模型检测复发腺瘤的AUROC为0.95(95%CI: 0.84-0.99),灵敏度90.0%、特异度87.0%。
  • 随访样本中m3、Fn和Ch组合检测复发腺瘤的AUROC为0.74(95%CI: 0.65-0.82),灵敏度81.3%、特异度55.4%。
  • 粪便免疫化学试验检测复发腺瘤的灵敏度为8.3%。

关键数值与推荐

  • 复发定义为息肉切除术后>6个月检出新的腺瘤。
  • 随访时m3、Fn和Ch变化组合检测复发腺瘤的AUROC为0.95(95%CI: 0.84-0.99),灵敏度90.0%、特异度87.0%。
  • 随访时m3、Fn和Ch组合检测复发腺瘤的AUROC为0.74(95%CI: 0.65-0.82),灵敏度81.3%、特异度55.4%。
  • 粪便免疫化学试验检测复发腺瘤的灵敏度为8.3%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously reported a panel of novel faecal microbiome gene markers for diagnosis of colorectal adenoma and cancer. AIM: To evaluate whether these markers are useful in detecting adenoma recurrence after polypectomy. METHODS: Subjects were enrolled in a polyp surveillance study from 2009 to 2019. Stool samples were collected before bowel preparation of index colonoscopy (baseline) and surveillance colonoscopy (follow-up). Fusobacterium nucleatum (Fn), Lachnoclostridium marker (m3), Clostridium hathewayi (Ch) and Bacteroides clarus were quantified in baseline and follow-up samples by quantitative polymerase chain reaction (qPCR) to correlate with adenoma recurrence. Recurrence was defined as new adenomas detected >6 months after polypectomy. Faecal immunochemical test (FIT) was performed for comparison. RESULTS: A total of 161 baseline and 104 follow-up samples were analysed. Among patients with adenoma recurrence, Fn and m3 increased (both P < 0.05) while Ch were unchanged in follow-up versus baseline samples. Among patients without recurrence, Fn and m3 were unchanged while Ch decreased (P < 0.05) in follow-up versus baseline samples. Logistic regression that included changes of m3, Fn and Ch at follow-up compared with baseline achieved an area under receiver operating characteristic curve (AUROC) of 0.95 (95%CI: 0.84-0.99) with 90.0% sensitivity and 87.0% specificity for detecting recurrent adenoma. Combination of m3, Fn and Ch at follow-up sample achieved AUROC of 0.74 (95%CI: 0.65-0.82) with 81.3% sensitivity and 55.4% specificity for detecting recurrent adenoma. FIT showed limited sensitivity (8.3%) in detecting recurrent adenomas. CONCLUSION: Our combinations of faecal microbiome gene markers can be potentially useful non-invasive tools for detecting adenoma recurrence.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Liang JQ, Zeng Y, Kwok G, et al. Novel microbiome signatures for non-invasive diagnosis of adenoma recurrence after colonoscopic polypectomy. Aliment Pharmacol Ther. 2022. PMID: 35224756. doi:10.1111/apt.16799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。